These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9002121)

  • 1. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones.
    Warren RW
    Pediatr Infect Dis J; 1997 Jan; 16(1):118-22; discussion 123-6. PubMed ID: 9002121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report.
    Hampel B; Hullmann R; Schmidt H
    Pediatr Infect Dis J; 1997 Jan; 16(1):127-9; discussion 160-2. PubMed ID: 9002122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
    LeBel M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofloxacin-induced renal insufficiency in cystic fibrosis.
    Moffett BS; Rosenstein BJ; Mogayzel PJ
    J Cyst Fibros; 2003 Sep; 2(3):152-4. PubMed ID: 15463865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin safety in a pediatric population.
    Jick S
    Pediatr Infect Dis J; 1997 Jan; 16(1):130-3; discussion 133-4, 160-2. PubMed ID: 9002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of quinolone antibiotics in the pediatric population.
    Grady R
    Pediatr Infect Dis J; 2003 Dec; 22(12):1128-32. PubMed ID: 14688586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
    Schaad UB; Wedgwood J; Ruedeberg A; Kraemer R; Hampel B
    Pediatr Infect Dis J; 1997 Jan; 16(1):106-11; discussion 123-6. PubMed ID: 9002119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient.
    Samuelson WM; Pleasants RA; Whitaker MS
    Ann Pharmacother; 1993 Mar; 27(3):302-3. PubMed ID: 8453165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin in children: is arthropathy a limitation?
    Singh UK; Sinha RK; Prasad B; Chakrabarti B; Sharma SK
    Indian J Pediatr; 2000 May; 67(5):386-7. PubMed ID: 10885214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis.
    Bald M; Ratjen F; Nikolaizik W; Wingen AM
    Pediatr Infect Dis J; 2001 Mar; 20(3):320-1. PubMed ID: 11303842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia.
    Mullen CA; Petropoulos D; Rytting M; Jeha S; Zipf T; Roberts WM; Rolston KV
    J Pediatr Hematol Oncol; 1998; 20(5):516-7. PubMed ID: 9787333
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of the quinolones in paediatrics.
    Schaad UB
    Drugs; 1993; 45 Suppl 3():37-41. PubMed ID: 7689449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the new quinolones in pediatrics.
    Schaad UB
    Isr J Med Sci; 1994; 30(5-6):463-8. PubMed ID: 8034505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance and safety of ciprofloxacin in paediatric patients.
    Black A; Redmond AO; Steen HJ; Oborska IT
    J Antimicrob Chemother; 1990 Dec; 26 Suppl F():25-9. PubMed ID: 2292542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential quinolone-induced cartilage toxicity in children.
    Camp KA; Miyagi SL; Schroeder DJ
    Ann Pharmacother; 1994 Mar; 28(3):336-8. PubMed ID: 8193422
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
    Redmond A; Sweeney L; MacFarland M; Mitchell M; Daggett S; Kubin R
    J Int Med Res; 1998 Dec; 26(6):304-12. PubMed ID: 10399112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons].
    Postnikov CC; Semiakin SI; Nazhimov VP; Kapranov NI
    Antibiot Khimioter; 2001; 46(10):11-3. PubMed ID: 11881187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis.
    Salam MA; Dhar U; Khan WA; Bennish ML
    Lancet; 1998 Aug; 352(9127):522-7. PubMed ID: 9716056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.